

September 7, 2020

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Contract on Distribution Operation of of Treakisym®, an Antineoplastic Drug by  
SymBio Pharmaceuticals Limited

TOHO HOLDINGS CO., LTD.(Headquarters: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter, “TOHO HOLDINGS”) hereby announces, its wholly owned subsidiary TOHO PHARMACEUTICAL CO., LTD.(Headquarters: Tokyo; President and Representative Director: Akira Umada) and other Kyoso Mirai Group companies were entrusted with distribution operation of the antineoplastic drug Treakisym® (hereinafter, “Treakisym®”) to be marketed by SymBio Pharmaceuticals Limited (Headquarters: Tokyo; Representative Director, President and Chief Executive Officer: Fuminori Yoshida; hereinafter, “SymBio”).

1. Contract background

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Symbio valued TOHO HOLDINGS's highly-functional logistics system, emergency response system, and contract performance history to launch Treakisym® by their own sales, and therefore the contract for the distribution of pharmaceuticals with SymBio was made on distribution operation of Treakisym®.

## 2. About Treakisym®

Treakisym® is a cytocidal anti-tumor drug, started to be used in Germany in the 1970s. It is currently indicated for the treatment of low-grade non-Hodgkin's lymphoma (low-grade NHL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), etc. in more than 50 countries.

SymBio obtained marketing approval for the indications of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma (low-grade NHL) and mantle cell lymphoma (MCL) in Japan in October 2010, and subsequently approved for the additional indication of chronic lymphocytic leukemia (CLL) in August 2016, approved for the Japanese drug manufacturing and marketing for Treakisym® Injection 25mg in September 2016, and approved for the additional indication of previously untreated low-grade NHL and MCL in December 2016. In addition, a phase III clinical study was started in August 2017 for the indication of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), which has the largest number of patients in the field of malignant lymphoma. In November 2019, SymBio announced that the results of the study, which was the primary endpoint, showed a better response rate than the expected response rate, and the approval application was filed in May 2020.

## 3. Performance outlook

Impact to consolidated performance is minor.